Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
Recursion Pharmaceuticals (RXRX) announced leadership changes and furnished Q3 materials. The Board appointed Najat Khan, Ph.D. as Chief Executive Officer and President, effective January 1, 2026, and named Christopher Gibson, Ph.D. as Chair of the Board, effective the same date.
Dr. Khan’s compensation includes an annual base salary of $680,000, plus equity awards granted on November 5, 2025 of $500,000 in restricted stock units and $500,000 in stock options, each vesting over four years, and an additional equity award expected, subject to compensation committee approval, with an aggregate value of at least $7,500,000 (half RSUs, half options) vesting over four years. She will receive enhanced severance under the company’s plan, including vesting acceleration for awards that would have vested during the 12 months after a Non‑CIC Qualifying Termination.
Dr. Gibson will serve as Advisor to the CEO under a 12‑month agreement beginning January 1, 2026, with group health premiums paid for up to 12 months and continued vesting of prior equity awards subject to service. Robert Hershberg, M.D., Ph.D. was appointed Vice Chair and Lead Independent Director. The company furnished a Q3 press release and investor presentations as exhibits.
Recursion Pharmaceuticals (RXRX) announced leadership changes and furnished Q3 materials. The Board appointed Najat Khan, Ph.D. as Chief Executive Officer and President, effective January 1, 2026, and named Christopher Gibson, Ph.D. as Chair of the Board, effective the same date.
Dr. Khan’s compensation includes an annual base salary of $680,000, plus equity awards granted on November 5, 2025 of $500,000 in restricted stock units and $500,000 in stock options, each vesting over four years, and an additional equity award expected, subject to compensation committee approval, with an aggregate value of at least $7,500,000 (half RSUs, half options) vesting over four years. She will receive enhanced severance under the company’s plan, including vesting acceleration for awards that would have vested during the 12 months after a Non‑CIC Qualifying Termination.
Dr. Gibson will serve as Advisor to the CEO under a 12‑month agreement beginning January 1, 2026, with group health premiums paid for up to 12 months and continued vesting of prior equity awards subject to service. Robert Hershberg, M.D., Ph.D. was appointed Vice Chair and Lead Independent Director. The company furnished a Q3 press release and investor presentations as exhibits.
Recursion Pharmaceuticals (RXRX) reported that Roche exercised its option for Recursion’s Microglia Map, described as a first-of-its-kind whole genome map of the brain’s immune cells. Under their 2021 collaboration with Genentech, Inc. and F. Hoffmann-La Roche Ltd, Recursion will receive an Acceptance Fee of $30 million.
This milestone reflects progress within the Roche–Recursion collaboration and results in a cash inflow to Recursion tied to delivery of the Microglia Map under the agreement.
Recursion Pharmaceuticals (RXRX) CEO and director reported a Form 4 for 10/23/2025. He converted 100,000 shares of Class B into Class A at $0 and sold 100,000 Class A shares at $5.70, pursuant to a Rule 10b5-1 plan adopted on May 12, 2025.
Following these transactions, he directly owned 954,229 Class A shares. The filing also lists remaining Class B holdings and vested/unvested stock options.
Insider transactions at Recursion Pharmaceuticals (RXRX): The CEO and director executed multiple transactions on 10/10/2025 under a Rule 10b5-1 plan adopted May 12, 2025. He acquired 120,000 Class B shares (convertible to Class A) at no cash cost, sold 100,000 Class A shares at $6.04 each, and gifted 20,000 Class A shares. After these moves, the reporting person directly owns 1,074,229 Class A-equivalent shares.
The filing also lists multiple outstanding stock options totaling significant potential dilution (options for ~3.2M Class A shares listed under different strike prices and vesting schedules) and indirect holdings via LLCs and a family trust. The sale, acquisition and gift were made under the disclosed trading plan and executed on the same date.
Recursion Pharmaceuticals, Inc. (RXRX) filed a Form 144 notice reporting a proposed sale of 100,000 Class A shares through Fidelity Brokerage, with an aggregate market value of $604,000 and an approximate sale date of 10/10/2025 on NASDAQ. The filing shows these shares were originally acquired as Founders Shares on 09/01/2016 and were issued as compensation.
The filing also discloses multiple recent sales by related parties during the past three months: combined transactions on 08/11/2025 and later dates totaling at least 978,875 Class A shares with gross proceeds shown (for example, a single sale of 500,000 shares on 08/11/2025 for $2,640,000). The notice includes the seller representations required under Rule 144 and the usual signature attestation about absence of undisclosed material adverse information.
Dean Y. Li, a director of Recursion Pharmaceuticals, Inc. (RXRX), acquired 1,961 shares of Class A common stock on 10/01/2025 at a reported price of $0 under the company’s Outside Director Compensation Policy. After the issuance, Mr. Li directly beneficially owns 1,238,528 shares. The filing also discloses indirect holdings: 1,422,048 shares held by the Dean Y. Li Revocable Trust, 136,981 shares held by the Dean Y. Li GRAT, and 421,000 shares held by the Dean Y. Li 2021 Family Trust. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Dar Zavain, a director of Recursion Pharmaceuticals (RXRX), reported acquiring 2,941 shares of Class A common stock on 10/01/2025. The shares were issued $0 under the issuer's Outside Director Compensation Policy. After the transaction, the reporting person beneficially owned 138,758 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025. This filing discloses routine director compensation in equity form.
Christopher Gibson, Chief Executive Officer and Director of Recursion Pharmaceuticals (RXRX), reported transactions dated 09/25/2025. The report shows the acquisition and simultaneous disposition of 100,000 shares of Class A common stock: a conversion/acquisition recorded at $0 and a sale of 100,000 shares at $4.76 per share, reducing his direct beneficial ownership of Class A shares from 1,054,229 to 954,229. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025. The report also lists indirect holdings through LAHWRAN-3 LLC, LAHWRAN-4 LLC and the Gibson Family Trust, and multiple outstanding stock options and convertible Class B shares that are convertible one-for-one into Class A shares. The form is signed by an attorney-in-fact on 09/26/2025.
Recursion Pharmaceuticals, Inc. (RXRX) Form 144 filed reporting a proposed sale of 100,000 Class A shares through Fidelity Brokerage Services with an approximate aggregate market value of $476,000, with an approximate sale date of 09/25/2025 on NASDAQ. The filing states the shares were originally acquired as Founders Shares on 09/01/2016 and were issued as compensation. The notice also discloses prior sales by related parties during the past three months totaling 817,875 Class A shares for gross proceeds of $3,386,380.00. The signer represents no undisclosed material adverse information exists and includes the standard attestation language required under Rule 144.
Recursion Pharmaceuticals insider transaction: The company's Chief Financial Officer reported a non-derivative transaction in the company's Class A common stock. The filing shows 7,057 shares were withheld as part of net settlement of restricted stock units to satisfy tax withholding at an average price of $4.83 per share, leaving the reporting person with 804,169 shares beneficially owned following the transaction. The filing identifies the transaction as an issuer withholding related to equity compensation rather than an open-market sale.
Recursion Pharmaceuticals insider transaction: The company's Chief Financial Officer reported a non-derivative transaction in the company's Class A common stock. The filing shows 7,057 shares were withheld as part of net settlement of restricted stock units to satisfy tax withholding at an average price of $4.83 per share, leaving the reporting person with 804,169 shares beneficially owned following the transaction. The filing identifies the transaction as an issuer withholding related to equity compensation rather than an open-market sale.